Semaglutide: A Promising Ally Against Alzheimer’s?
In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.
Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.
Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.
Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.
Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.
According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.
“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”
Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.
For more information, please contact Patty Zamora at [email protected].
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
The title insurance industry is entering 2026 with a renewed focus on technology, operational efficiency, and stronger agent support after years of volatility. Leaders from major underwriters report rising transaction activity, improved affordability, and a surge in automation and fraud‑prevention tools—signs that smarter systems and better training will define the next wave of growth.
A multistate crackdown has sent shockwaves through the mortgage industry as Patrick Terrance Donlon, CEO of Trusted American Mortgage, accepted a sweeping settlement that bans him from working as a mortgage loan originator in 21 states—19 of them permanently. Regulators say Donlon had another individual complete his mandatory licensing and continuing‑education courses, a violation that triggered a coordinated investigation and a $31,000 penalty. The case underscores regulators’ growing intolerance for education fraud and serves as a sharp reminder to industry professionals: cutting corners on licensing can end careers.
Florida’s once‑booming housing market is cooling fast as rising insurance premiums, increasing foreclosures, and expanding flood zones push buyers to back out of deals and force sellers to cut prices. With insurance now adding thousands to annual housing costs, professionals across real estate, mortgage, and insurance are navigating a dramatically shifting landscape that’s redefining affordability in the Sunshine State.
Florida begins 2026 with a wave of more than 250 new laws now in effect, impacting healthcare, insurance, real estate, and consumer protections statewide. From free breast cancer screenings for state employees to tighter pet insurance regulations, mandatory healthcare refund rules, enhanced animal‑cruelty penalties, and new condo‑management requirements, these updates carry major implications for professionals navigating Florida’s evolving regulatory landscape.
Florida’s barrier islands may offer postcard-perfect beaches and soaring real estate demand, but they’re also some of the most fragile and costly places to build in the United States. With 765,000 residents living on land that shifts, sinks, and takes the brunt of every major hurricane, the financial and insurance risks are accelerating fast. From billion‑dollar beach rebuilds to towers settling into the sand, today’s coastal development challenges are reshaping conversations around property values, disclosure, and long‑term resilience. For real estate professionals, understanding these risks isn’t just smart — it’s becoming essential.
A Cedar City development is turning heads with its fresh approach to affordability. The team behind Temple View Commons is delivering luxury‑inspired twin homes at prices below the local median by using a small, hands‑on staff and cutting traditional costs like realtor commissions. In a tight Utah housing market where inventory is scarce and prices remain high, their strategy offers a realistic path to homeownership without sacrificing high‑end finishes.
Title Insurance Leaders Double Down on Tech and Efficiency to Drive 2026 Market Momentum Gallery
